Medical Patent News

RSS

Benitec announces USPTO's reversal of all previous rejections in '099 Graham patent appeal

Benitec Limited, a leading Australian based company specialising in RNA interference (RNAi) technology is pleased to announce the United States Patent and Trademark Office's (USPTO) Board of Patent Appeals and Interferences decision ("the Decision") reversing all previous rejections in the US 6,573,099 (the '099 Graham patent) appeal.

4 Oct 2010

BSD receives patent for heat therapy applicators

BSD Medical Corporation announced today that a patent has been issued to the Company for a new class of heat therapy applicators (antennas). The United States (US) patent office issued the new patent, Transparent electromagnetic applicator and hyperthermia treatment method, to BSD for a unique design for antennas that provides significant benefits for heat therapy applications.

30 Sep 2010

NEUROKIN accentuates its leadership in the treatment of acute neurological diseases

Bbiotechnology company NEUROKIN, dedicated to the development of neuroprotective drugs to treat acute neurological diseases, announces today that the European Patent Office (EPO) has granted patent EP 1998778 protecting the use of NK-102, its most advanced drug candidate. This first European award constitutes an important milestone for NEUROKIN. An application for registration is under way in Brazil, Canada, China, USA and Japan.

29 Sep 2010

National Jewish Health's liposome-based vaccine receives US patent

National Jewish Health has received a US patent for a new kind of vaccine, which uses a small lipid bubble to deliver an antigen and DNA adjuvant. Chairman of Pediatrics Erwin Gelfand, MD, and former National Jewish Health Professor of Medicine Steve Dow, PhD, developed the new liposome-based adjuvant.

29 Sep 2010

Generex Biotechnology receives new patent for buccal drug delivery system

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has been awarded a new patent in Canada.

29 Sep 2010

Oncolytics Biotech receives patent for modified reovirus variant

Oncolytics Biotech Inc. today announced that it has been granted U.S. Patent, 7,803,385 entitled Reoviruses Having Modified Sequences. The patent claims cover methods for making and using modified reoviruses, and pharmaceutical compositions that include modified reoviruses.

28 Sep 2010

USPTO issues Notice of Allowance for INSORB Skin Closure technology

Incisive Surgical, Inc. today announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for another key patent application, "Mechanical Method and Apparatus for Tissue Fastening." The allowed claims include subject matter covering the method of the INSORB Skin Closure technology and specific stapler features.

28 Sep 2010

HealthWyse secures patent for Remote Personnel Tracking program to prevent Medicare fraud

HealthWyse, a leading provider of home health and hospice agency automation software, announced today that it has secured a patent for its Remote Personnel Tracking program to help homecare agencies keep track of their employees and prevent Medicare fraud. HealthWyse will showcase its Remote Personnel Tracking Program at the National Association for Home Care and Hospice (NAHC) 29th Annual Meeting & Exposition, held October 2 - 6 in Dallas, Texas.

28 Sep 2010

Japanese Patent Office issues patent for ZIOPHARM Oncology's darinaparsin

ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.

28 Sep 2010

Perrigo files NDA with FDA for generic Zegerid OTC

Perrigo Company announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) for omeprazole 20mg/sodium bicarbonate 1100mg, the generic equivalent of Zegerid OTC™, and that it provided prior notice of this filing to Schering-Plough HealthCare Products, Inc. a subsidiary of Merck & Co., Inc., the owner of the brand regulatory approval and the Curators of the University of Missouri, the listed patent owner.

24 Sep 2010

Teva asserts infringement of 4 COPAXONE-related patents by Mylan, files complaint in U.S. District Court

Teva Pharmaceutical Industries Ltd. announced today it has filed a complaint in the U.S. District Court for the Southern District of New York against Mylan asserting infringement of four patents related to the characterization of COPAXONE® (glatiramer acetate injection). The latest of these patents expires in February 2020.

22 Sep 2010

Five Prime Therapeutics receives patent for lead oncology product

Five Prime Therapeutics, Inc. today announced it has been issued two patents, U.S. Patent No. 7,678,890 and European Patent No.1910542B1, with claims covering various engineered Fibroblast Growth Factor Receptor ("FGFR") fusion proteins, including composition of matter claims for its lead oncology product, FP-1039.

21 Sep 2010

Celera receives patent on KIF6 gene variant

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,799,530 relating to methods of determining heart attack risk by detecting the KIF6 gene variant and reduction of such increased risk by statin therapy.

21 Sep 2010

ConfiDisc Syringe Injection System granted U.S. patent

Product innovators Chris and Sonia Hillios are pleased to announce that they have been granted a patent by the U.S. Patent and Trademark Office pertaining to their new syringe injection system, ConfiDisc(R).

21 Sep 2010

Talecris Biotherapeutics announces 2010 eALTA award recipients

Talecris Biotherapeutics GmbH announced yesterday the recipients of the 2010 European alpha1-antitrypsin Laurell's Training Awards (eALTA). The annual awards, sponsored by Talecris, provide two fellowships of 50,000 euros to young investigators whose research aims to enhance the understanding and treatment of alpha1-antitrypsin deficiency (AAT deficiency).

21 Sep 2010

ABL receives new patent for TherapyEdge and ViroScore technology

Advanced Biological Laboratories (ABL) S.A., a biomedical company engaged in the development and commercialization of personalized healthcare electronic medical record systems coupled with expert rules using decision support tools, is pleased to announce today that the Canadian Intellectual Property Office has issued a Notice of Allowance and the Patent Office of India has issued a new patent for our patent applications derived from our U.S. Patent Nos. 6,081,786 and 6,188,988 to Barry et al.

21 Sep 2010

Harbor BioSciences granted US patent for Triolex metabolic disease and anti-inflammation drug candidate

Harbor BioSciences, Inc. today announced that the company has received patent No. 7,776,845 from the United States Patent and Trademark Office which covers its lead metabolic disease and anti-inflammation drug candidate Triolex (HE3286). The patent claims cover compounds including Triolex and formulations that contain the drug or the other claimed compounds.

20 Sep 2010

Stereotaxis receives 100th patent for interventional medicine

Stereotaxis, Inc. today announced that the U.S. Patent and Trademark Office granted the Company its 100th patent, a major intellectual property milestone. The 100th patent, U.S. patent No. 7,772,950, covers the "Method and Apparatus for Dynamic Magnetic Field Control Using Multiple Magnets." The 100th patent reflects Stereotaxis' ongoing commitment to innovate and protect its leading position in robotic solutions for interventional medicine.

20 Sep 2010

HemCon to appeal permanent injunction on Marine Polymer patent

HemCon Medical Technologies, Inc., announced today that it will appeal a permanent injunction entered by a US District Court in New Hampshire based on a patent held by Marine Polymer Technologies, Inc.

18 Sep 2010

Shrink Nanotechnologies files patent for CellAlign tissue engineering technology

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that certain patent applications related to its advanced tissue engineering technology platform, CellAlign, have been filed.

17 Sep 2010